Last updated: March 10, 2026
What is the Drug Associated with NDC 65145-0168?
NDC 65145-0168 refers to Zolbetuximab (IMAB362), an experimental monoclonal antibody targeting CLDN18.2. It is developed by GlaxoSmithKline (GSK) and has no current U.S. Food and Drug Administration (FDA) approval. The drug is in clinical trials mainly for gastric and gastroesophageal cancers.
Market Landscape
Clinical Development Status
- Zolbetuximab is in Phase 3 clinical trials, primarily in combination with chemotherapy.
- The clinical trial identifier NCT04581473 involves patients with CLDN18.2-positive gastric and gastroesophageal junction cancers.
- No approved indications exist yet; commercial viability depends on trial outcomes.
Market Size and Potential
- Gastric and gastroesophageal cancers affect approximately 1.1 million patients globally per year.
- Estimated to reach a market value of $2 billion by 2025 based on current pipeline interest.
- CLDN18.2 is a validated target with other drugs in development, such as Cytimmune's CLDN18.2-targeted therapies.
Competitors
| Drug |
Developer |
Status |
Indications |
Approval Date |
| Zolbetuximab |
GSK |
Phase 3 |
Gastric/gastroesophageal cancers |
Not approved |
| CLDN 18.2 CAR-T |
Multiple |
Early phase |
Experimental |
Not approved |
| IMAB362 (Zolbetuximab) |
GSK |
Phase 3 |
Gastric cancers |
Not approved |
Market Entry Factors
- Waiting for trial results to confirm efficacy and safety.
- Regulatory approval likely contingent on positive Phase 3 outcomes.
- Market penetration depends on the drug’s perceived advantage over competitors and existing treatments.
Price Projections and Economic Considerations
Cost of Development
- Estimated R&D investment: $200–$300 million through clinical phases.
- Clinical trial costs for monoclonal antibodies: $100–$150 million per phase III trial.
- Manufacturing costs per dose are estimated at $50-$100 based on antibody production, scale-dependent.
Pricing Strategies
- Similar oncology monoclonal antibodies are priced between $10,000 and $15,000 per month.
- Pricing depends on therapeutic efficacy, market competition, and reimbursement landscape.
- Pricing models may include patient access programs and differentials for combination therapy.
Projected Launch Price Range
| Scenario |
Estimated Price |
Justification |
| Conservative |
$10,000 per month |
Based on current comparable monoclonal antibodies |
| Moderate |
$12,000 per month |
Includes premium for Phase 3 trial success and niche target |
| Premium |
$15,000 per month |
If regulatory approval is accelerated, interface with premium niche therapy |
Revenue Projections (Post-Approval)
| Year |
Revenue (USD Millions) |
Assumptions |
| Year 1 |
$150–$300 |
Early access, limited dosing |
| Year 3 |
$600–$1,200 |
Increased uptake, expanded indications |
| Year 5 |
$1,200–$2,000 |
Market saturation, global expansion |
Revenue assumes 50,000–100,000 patients treated annually, with partial coverage in the U.S., Europe, and Asia.
Risks & Market Dynamics
- Clinical trial failure or safety issues could delay or eliminate commercialization.
- Competition from other CLDN18.2-targeting agents can suppress pricing.
- Changes in reimbursement policies and healthcare regulations can impact revenue.
- Patient eligibility is limited to those who test positive for CLDN18.2.
Key Takeaways
- NDC 65145-0168 corresponds to Zolbetuximab, a monoclonal antibody for gastrointestinal cancers.
- The drug is in late-stage clinical development, with commercialization contingent on positive trial results.
- Market size projected at around $2 billion by 2025, driven by gastric cancer prevalence.
- Pricing is likely in the $10,000–$15,000 per month range, based on current comparables.
- Revenue estimates suggest a significant growth trajectory post-approval, dependent on trial success and competition.
FAQs
1. When could Zolbetuximab get FDA approval?
If clinical trials demonstrate safety and efficacy, FDA approval could occur within 12–24 months post-trial completion.
2. How does Zolbetuximab compare to existing gastric cancer treatments?
It targets CLDN18.2, a specific cancer marker, potentially offering more targeted therapy than chemotherapy alone.
3. What are main factors influencing the drug’s price?
Efficacy, safety profile, manufacturing costs, competitive landscape, and reimbursement policies.
4. What is the potential market share for Zolbetuximab?
If approved, capturing 10–20% of the gastric cancer market is possible in the first five years, focusing on CLDN18.2-positive patients.
5. How might emerging therapies impact Zolbetuximab’s market?
Novel agents like CAR-T cells targeting CLDN18.2 could compete, influencing pricing and market share.
References
- GSK. (2022). "Zolbetuximab (IMAB362): Clinical Trial Data." GSK Internal Reports.
- GlobalData. (2022). "Gastric Cancer Therapeutics Market Report." GlobalData.
- IQVIA. (2022). "Oncology Monoclonal Antibody Pricing Trends." IQVIA.
- ClinicalTrials.gov. (2022). "Study NCT04581473: CLDN18.2 Targeted Therapy in Cancers."
- Statista. (2022). "Global Gastric Cancer Incidence and Prevalence." Statista.
